These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15050159)

  • 1. The expression of intestinal CYP3A4 in the piglet model.
    Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
    Transplant Proc; 2004 Mar; 36(2):361-3. PubMed ID: 15050159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The colon displays an absorptive capacity of tacrolimus.
    Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
    Transplant Proc; 2004 Mar; 36(2):364-6. PubMed ID: 15050160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
    Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic drug monitoring of immunosuppresants].
    Hashida T; Inui K
    Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cyclosporin A and tacrolimus concentrations in whole blood between jejunal and ileal transplanted rats.
    Ogino Y; Kobayashi E; Fujimura A
    J Pharm Pharmacol; 1999 Jul; 51(7):811-5. PubMed ID: 10467956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased tacrolimus trough levels in association with severe diarrhea, a case report.
    Asano T; Nishimoto K; Hayakawa M
    Transplant Proc; 2004 Sep; 36(7):2096-7. PubMed ID: 15518758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients.
    Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High trough levels of oral FK506 induced by loss of small intestine.
    Sano N; Nio M; Shimaoka S; Ishii T; Amae S; Wada M; Ohi R
    Pediatr Transplant; 2001 Dec; 5(6):434-8. PubMed ID: 11737769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum.
    Canaparo R; Finnström N; Serpe L; Nordmark A; Muntoni E; Eandi M; Rane A; Zara GP
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1138-44. PubMed ID: 17880367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus.
    Shimomura M; Masuda S; Saito H; Sakamoto S; Uemoto S; Tanaka K; Inui K
    J Surg Res; 2002 Apr; 103(2):215-22. PubMed ID: 11922737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation.
    Reggiani P; Gatti S; Rossi G; Orsenigo R; Maggi U; Leoni L; Ceccherelli F; Colledan M; Gridelli B; Piazzini-Albani A; Galmarini M; Andreani P; Bardella MT; Langer M; Doglia M; Fassati LR; Galmarini D
    Transplant Proc; 1996 Oct; 28(5):2587-8. PubMed ID: 8907965
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
    Masuda S; Goto M; Okuda M; Ogura Y; Oike F; Kiuchi T; Tanaka K; Inui K
    Transplant Proc; 2005 May; 37(4):1728-9. PubMed ID: 15919446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
    Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
    Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN; Barama A; Poirier C; Vinet B; Roger M
    Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interaction between sildenafil and calcineurin inhibitors in renal transplant recipients with erectile dysfunction].
    Cofán F; Gutiérrez R; Beardo P; Campistol JM; Oppenheimer F; Alcover J
    Nefrologia; 2002; 22(5):470-6. PubMed ID: 12497749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation.
    Lemahieu WP; Maes BD; Verbeke K; Vanrenterghem Y
    Kidney Int; 2005 Mar; 67(3):1152-60. PubMed ID: 15698457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.